


## PROBLEM

Infections of the urinary tract in catheterized patients are one of the most common hospital-acquired infections. Current diagnosis is reactive, being triggered by patient symptoms that lead to a medical decision for urine collection and lab analysis. The results can take up to 3 days to be obtained, costing 9 to 150 €, depending on the technique. This delay results in late intervention, leading to longer hospital stays, increased complication rates, higher costs, and additional workload for healthcare professionals.



## SOLUTION

TimeUp is a medical device for continuous monitoring of urine to detect *E. coli*, the leading agent of urinary tract infections (UTI), before symptoms. The device is attached to the urinary catheter and enables continuous, decision-free, and sampling-free detection of this bacterium. The results can be obtained in 24h at a significantly lower cost (~5€). This enables healthcare professionals to early identify patients at risk of developing UTI and take preventive clinical actions, supporting improved patient management and reducing infection-related costs.

## BUSINESS MODEL

The business model is focused on achieving the CE marking following clinical validation, and then pursuing the licensing or technology transfer agreements with leading urinary catheter manufacturers (e.g., BD, Teleflex, Coloplast, B Braun, Hollister). These companies already have strong market penetration and established distribution channels.

TimeUp was designed to be integrated in existing urinary catheters, enabling product differentiation through enhanced clinical value in the manufacturers portfolios.

## TEAM & CAP TABLE

- 19.996% - Marta Santos (CEO)
- 19.996% - Susana Alarico (CSO)
- 19.996% - Paula Ferreira
- 19.996% - Igor Tiago
- 19.996% - Marcos Mariz
- 0.020% - Portugal Ventures

## CONTACT

✉ [marta.santos@timeuphealth.com](mailto:marta.santos@timeuphealth.com)

🌐 <https://timeuphealth.com/timeup/>

## FUNDING NEED - 250 K€

**Project of > 1 M€**

**~800 k€ already secured**

653 K€ - PT2030 (public funds)

150 K€ - Portugal Ventures (VC)

